Clinical implications of micrornas in aml

Targeted Therapy of Acute Myeloid Leukemi

Volumn , Issue , 2015, Pages 699-705

  Ranganathan, Parvathi ^a   Garzon, Ramiro ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Antisense; Biomarkers; Micrornas

Indexed keywords

EID: 84944556210     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4939-1393-0_37     Document Type: Chapter

References (24)

1. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281–297
2. Blum W, Garzon R et al (2010) Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci U S A 107:7473–7478
3. Blum W, Schwind S et al (2012) Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia. Blood 119:6025–6031
4. Calin GA, Croce CM (2006) MicroRNA signatures in human cancers. Nat Rev Cancer 6:857–866
5. Croce CM (2009) Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 10:704–714
6. Dixon-McIver A, East P et al (2008) Distinctive patterns of microRNA expression associated with karyotype in acute myeloid leukaemia. PLoS One 3:e2141
7. Ebert MS, Neilson JR et al (2007) MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods 4:721–726
8. Elmen J, Lindow M et al (2008a) LNA-mediated microRNA silencing in non-human primates. Nature 452:896–899
9. Elmen J, Lindow M et al (2008b) Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res 36:1153–1162
10. Garzon R, Croce CM (2008a) MicroRNAs in normal and malignant hematopoiesis. Curr Opin Hematol 15:352–358
11. Garzon R, Volinia S et al (2008b) MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood 111:3183–3189
12. Garzon R, Liu S et al (2009) MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood 113:6411–6418
13. Garzon R, Marcucci G et al (2010) Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 9:775–789
14. Gumireddy K, Young DD et al (2008) Small-molecule inhibitors of microrna miR-21 function. Angew Chem Int Ed Engl 47:7482–7484
15. Kota J, Chivukula RR et al (2009) Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137:1005–1017
16. Krutzfeldt J, Rajewsky N et al (2005) Silencing of microRNAs in vivo with ‘antagomirs’. Nature 438:685–689
17. Lee Y, Kim M et al (2004) MicroRNA genes are transcribed by RNA polymerase II. EMBO J 23: 4051–4060
18. Liu S, Wu LC et al (2010) Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. Cancer Cell 17:333–347
19. Marcucci G, Mrozek K et al (2011) The prognostic and functional role of microRNAs in AML. Blood 117:1121–1219
20. Marcucci G, Radmacher MD et al (2008) MicroRNA expression in cytogenetically normal acute myeloid leukemia. N Engl J Med 358:1919–1928
21. Sandhu S, Garzon R (2011) Potential applications of microRNAs in cancer diagnosis, prognosis, and treatment. Semin Oncol 38:781–787
22. Schwind S, Maharry K et al (2010) Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 28:5257–5264
23. Stenvang J, Petri A et al (2012) Inhibition of microRNA function by antimiR oligonucleotides. Silence 3:2–17
24. Young DD, Connely CM et al (2010) Small molecule modifiers of microRNA miR-122 function for the treatment of hepatitis C virus infection and hepatocellular carcinoma. J Am Chem Soc 132:7976–7981